BioSpaceOriginal article
Sanofi pauses mid-stage lung study amid new CEO’s ‘rigorous portfolio prioritization’
DupixentNegative
AI Analysis
Summary
Sanofi has paused a mid-stage lung study as part of new CEO Belén Garijo's portfolio prioritization review focusing on scientific merit and long-term value.
Clinical Trial Data
Phase
2
Outcome Details
mid-stage lung study paused
Importance:5/10
Sentiment:
-0.60
pipeline updatestudy pauseportfolio prioritizationCEO decisionlung disease
Related Companies
Read the original article
Published by BioSpace on August 6, 2026 12:24 PM